



Redefining Druggable Targets

Simplified Deck

Johnson+Johnson INNOVATION | JLABS

HTuO Biosciences Inc.

OVERVIEW

Physics-enabled software for drug discovery



Founded in October 2020



\$2.5M USD raised to date
\$780k in non-dilutive funding




Team of 12 and growing rapidly



Currently preparing for
commercialization




Members of SF JLABS




Optimizing drug compounds is a \$1.2B USD market annually, and represents the final, biggest gap in drug development

HTuO's Beachhead market



Traditional methods underperform

Newer AI methods are limited by a lack of training data



Introducing HTuO's AtomForge:

Accurate and Reliable molecular interaction predictions.

Opening the door to new drugs and new modalities,
and **Redefining Druggable Targets** .

Current CADD tools are still limited

During drug discovery process

Limited physics models

limit target characterization

Existing CADD tools can only be applied to about 30% of the drug discovery market

Low accuracy of prediction

in hit discovery

Unnecessary synthesis of inactive compounds consumes precious resources

Low precision

during hit optimization

Margin of error is too large to efficiently optimize the molecule



As a consequence, CADD is often used as a backward validation and the resource intensive experiential wet labs still drive the discovery process, for a limited set of targets.

Reliable Biology Solutions

Can accurately work without training data

Based on Real Chemistry

No overfitting, No compromises.

Reducible

Every detail and prediction is explained

Physics Based

Consistently correct answers, no "Hallucinations"

Cost Efficient

Cost of solving biology scaled problems

Scalable

Biological size systems

No Training Data Limitations

Generalized platform works on any chemistry

Non AI/ML Tools

Focus on real solutions, not approximations



AtomForge

High Throughput

**For Drug
Discovery**



AtomForge

High Accuracy

**For Drug
Optimization**

A platform for drug ranking, with applications in design, optimization and de-risking

And for expanding the range of what's "druggable".

Our Business Model



Foundation: Strategic Partnerships

- Faster revenue generation
- Opportunity to learn from customers
- Focus on **Small Molecules**

Target: Partner-initiated

Deal terms: Upfront & research fees

Deal type: High volume & highly diversified

IP position: Partner keeps most IP



Expansion 1: Co-development, drug discovery

- Longer term projects
- more risk offset by larger reward
- Small Molecules and Custom Modalities

Target: Partner- or HTuO-initiated

Deal terms: Upfront, milestone & royalty payments

Deal type: Low volume with focused therapeutic area

IP position: Split between partner & HTuO



Expansion 2: In-House drug discovery

- More Modalities
- "Hard to Drug" Targets
- **Early Clinical Asset Sales**

Target: HTuO-initiated

Deal terms: Asset Purchase & Royalty payments

Deal type: Early Clinical Asset Sales

IP position: Wholly owned

Small molecules are still a huge market opportunity



>50% of FDA approval

In 2023, 38 out of 70 approved therapies



Most invested modality by VCs

32% small molecules
23% antibody/protein
23% peptides
9% CGT
13% other



\$52B USD Annual Market

90% of all drugs sold are small molecules



Can access hard to reach targets

Can target cryptic sites and nucleic acids



Easy to manufacture & transport

Well established global manufacturing sites and distribution networks



Can be administered orally

Pill vs injectables improves patient adherence and frees up hospital capacity

Input Required:

Protein Structure

PDB or equivalent 3D structure needed

Docking Site

PDB or equivalent 3D structure needed

Applications:

Modality Agnostic


From small molecules to peptides and Molecular Glue

Target Agnostic

Works on both well known and novel targets

Disease Agnostic

Not limited by indication



**For Drug
Discovery**



**For Drug
Optimization**



Optimized Minimization
Best Candidates Ranked
Time required:
**1 hour on 1 CPU, per
compound.**

1000+ Molecules



Free Energy Perturbation in Solvent
Best Candidates Explored
Time required: **2 weeks**

~ 50-100 Molecules

Drug discovery partnership funnel overview



Qualified Leads

23 leads

- 23 companies waiting for protein-ligand binding data
- Mix of big pharma, emerging pharma & medium sized biotech
- Potential projects from drug optimization, osteoporosis, Alzheimer's, oncology, and molecular glue



Partnership discussions

2 ongoing

- 2 Currently in discussions with European drug discovery & development companies



Validation projects

2 ongoing

- 1 Completed 3 of 3 milestones set through JLABS
 - Unlocks opportunities with 6 more big pharma
- 1 USA drug discovery & development company




Research collaborations

1 complete

- Work completed on CACHE 6 competition in partnership with Molecular Forecaster
- Ongoing pilot for a West Coast Biotech company to rank drugs

AtomForge's Foundational Technology Creates Market Optionality



Optionality of Exit Strategy and Comparables

HTuO Biosciences Drug Discovery Company

Acquisition

High demand by the pharmaceutical industry for more accurate computational chemistry solutions will make HTuO/AtomForge a target for acquisition by leading pharmaceutical companies.

Drug Discovery

Potential to generate high revenue from research funding and milestone payments through drug discovery collaborations that utilize AtomForge.

IPO

Access to capital that will allow HTuO to pursue multiple internal drug discovery projects and multiple drug discovery co-development partnerships.



Acquired by Recursion for \$688M in November 2024
(2023 revenue: \$25.6M)



Acquired by Roivant for \$450M in January 2021
(2020 Revenue: \$9M)



Partnership with Novartis
\$150M upfront + \$2.3B in milestones (2024)



\$140M drug discovery partnership with Sanofi (2023)



\$1.4B market cap
(2023 revenue: \$217M)



\$800M market cap
(2023 revenue: \$25.5M)

Leadership

Dr. Anthony Fejes, CEO and Co-Founder

Scientific Co-Founder, Zymeworks

Sr. Director of Bioinformatics, Fabric Genomics

Head of Bioinformatics, Tenaya Therapeutics

Jacek Mis, Director of Business Development

Senior Business Development Manager, Aspect Biosciences

Business Development Manager, AdMare

Bioinnovations

Co-Founder, Hive Business Solutions

Jason Loscher, Director of Technology

Software Development Manager, Synthesis Health

Lead Software Developer, 1QBit

Lead Software Developer, Simba Technologies

Team

R&D Team

Dr. Yi-Hsuan Lin, R&D Lead

Emily Wilson, Scientist - Optimization

Navid Ahmed Ali, Software Engineer

Software

Vladimir Nicolić, Senior Software Engineer

Jordan Han, Software Engineer

Computational Chemistry

Dr. Ahmed Ayoub, Lead Scientist -

Computational Chemistry

Dr. Mohammad Salem, Scientist Computational

Chemistry

Operations

Dr. Mathew Neal, Application Scientist

Cian Kearns, Administrative Assistant

Board

Neil Klompas

Chief Executive Officer, Augurex Life Sciences

Director; Independent Board Member, NervGen Pharma Corp.

Former President and Chief Operating Officer, Zymeworks

Alvin Chubbs

Investor, EFund

Senior Director R&D, Radisys Corporation

VP R&D, Wenco International Mining Systems


Director, Conveda

Chris Bradbury

Angel Investor, SWAN Venture Fund

Sr. Manager, Caiman Consulting Corp.


	USD
End of 2025 Burn Rate:	<\$100k/mo
Current Runway:	Jan 2026
Amount Raised to date:	\$2.5M
Non-dilutive Funding (Grants) to date:	\$763k



Revenue based solely on the foundation business model.


Foundation - \$4M USD

- Organic growth tied to revenue from partnerships
- Focus on partnerships
- 2 year Runway
- Milestones tied to Revenue



Extension I - Additional \$4M USD

- Growth to support more rapid commercialization
- Expand Executive team
- Separate divisions for partnership model and in-house model
- 3 year Runway
- Milestones tied to clinical asset development



THANK YOU.



anthony@htuo.bio



htuobio.com



linkedin.com/company/htuobio